R 0797070
Alternative Names: R-0797070Latest Information Update: 08 Dec 2023
At a glance
- Originator Ribocure Pharmaceuticals
- Class Amino sugars; Antihypertensives; Drug conjugates; Small interfering RNA
- Mechanism of Action Angiotensinogen expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase Unknown Hypertension
Most Recent Events
- 10 Oct 2023 R 0797070 is available for licensing as of 10 Oct 2023. https://ribocure.com/science/
- 10 Oct 2023 Investigation in Hypertension in Sweden (Parenteral) (before August 2023)
- 25 Aug 2023 pharmacodynamics data from a preclinical study in hypertension presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2023)